Unjha Formulations Ltd Stock Price Today (NSE: UNJHAFOR)
Fundamental Score
Unjha Formulations Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Unjha Formulations Ltd share price today is ₹19.50, up +0.00% on NSE/BSE as of 23 June 2026. Unjha Formulations Ltd (UNJHAFOR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹10.96 (Cr). The 52-week high for UNJHAFOR share price is ₹30.40 and the 52-week low is ₹18.60. At a P/E ratio of 10.74x, UNJHAFOR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 13.97% and a debt-to-equity ratio of 0.00.
Unjha Formulations Ltd Share Price Chart — NSE/BSE Historical Performance
Unjha Formulations Ltd share price chart: -7.88% return over the past month. 52-week high ₹30.40, 52-week low ₹18.60.
Unjha Formulations Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹19.50 | ₹19.50 | ₹19.50 | ₹19.50 | 8.29K (Cr) | |
| ₹19.50 | ₹19.50 | ₹19.50 | ₹19.50 | 105.00 (Cr) | |
| ₹19.00 | ₹19.50 | ₹19.00 | ₹19.50 | 2.37K (Cr) | |
| ₹19.30 | ₹19.30 | ₹19.30 | ₹19.30 | 15.00 (Cr) | |
| ₹20.00 | ₹20.00 | ₹19.26 | ₹19.26 | 262.00 (Cr) | |
| ₹19.40 | ₹20.00 | ₹19.40 | ₹20.00 | 1.10K (Cr) | |
| ₹19.33 | ₹19.33 | ₹19.33 | ₹19.33 | 6.00 (Cr) | |
| ₹18.72 | ₹19.34 | ₹18.72 | ₹19.34 | 1.43K (Cr) | |
| ₹19.25 | ₹19.30 | ₹19.25 | ₹19.30 | 340.00 (Cr) | |
| ₹20.00 | ₹20.00 | ₹19.00 | ₹19.02 | 2.99K (Cr) |
Unjha Formulations Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹19.50 | ₹19.50 | ₹19.50 | ₹19.50 | +0.00% | |
| ₹21.50 | ₹21.50 | ₹18.72 | ₹19.50 | -9.30% | |
| ₹21.50 | ₹22.94 | ₹18.60 | ₹22.00 | +2.33% | |
| ₹21.90 | ₹22.40 | ₹19.00 | ₹20.29 | -7.35% | |
| ₹22.50 | ₹23.90 | ₹20.50 | ₹21.69 | -3.60% | |
| ₹25.00 | ₹26.00 | ₹20.11 | ₹22.00 | -12.00% | |
| ₹25.95 | ₹26.00 | ₹23.22 | ₹25.00 | -3.66% | |
| ₹24.00 | ₹27.80 | ₹22.11 | ₹25.68 | +7.00% | |
| ₹25.00 | ₹25.50 | ₹23.00 | ₹24.00 | -4.00% | |
| ₹24.82 | ₹27.40 | ₹24.00 | ₹25.43 | +2.46% | |
| ₹25.60 | ₹25.99 | ₹23.39 | ₹24.77 | -3.24% | |
| ₹23.99 | ₹30.40 | ₹21.40 | ₹25.90 | +7.96% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Micro-cap ayurvedic play with negative free cash flow and high illiquidity risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The stock sank to a 52-week low on April 7, 2026. However, promoter shareholding remains stable at 36.92% as of April 1, 2026.
CORE STORY (THE REAL GAME)
- Low P/E relative to industry
- Recent profit growth in Q3FY26
- Stable promoter holding
- Sustained revenue and profit growth
- New product launches
- Increased market awareness of ayurvedic products
- Micro-cap illiquidity
- Negative free cash flow
- Low operating profit margin
- Dependence on single product (isabgol)
Promoter holding steady at 36.92%, no FII/DII interest.
Indian pharma sector projected to reach $130 billion by 2030, but Unjha's micro-cap status means it may not benefit.
No. Free Cash Flow 5Y: ₹-0.16 Cr
If Unjha can diversify its product line and improve its cash flow, it could be a long-term compounder. But for now, it's too risky.
Primary Thesis Risk
Illiquidity will trap you.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Unjha Formulations Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Unjha Formulations Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of UNJHAFOR across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Excellent ROCE Performance (18.06%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 10.74 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (845.45%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Margin Pressure Concerns (2.84%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Negative Free Cash Flow (₹-0.16 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Unjha Formulations Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Unjha Formulations Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Unjha Formulations LtdUnjha Formulati...Selected✓ UNJHAFOR • 531762 | 38.8/100 | ₹19.50₹20 | ₹10.96₹10.96 | 10.74Average 10.7 Average | 13.97%Average 13.97% Average | 18.06%Good 18.06% Good | 0.00Excellent 0.0 Excellent | 5.75%Good 5.75% Good | 5.53%Good 5.53% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1796.50₹1797 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6553.50₹6554 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.30₹1390 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1290.40₹1290 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2262.90₹2263 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1091.20₹1091 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.20₹2320 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5314.50₹5315 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Unjha Formulations Ltd PE Ratio History
Historical price-to-earnings ratio for UNJHAFOR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.91 | ₹25.00 | 27.5x |
| FY 2024 | ₹0.62 | ₹30.37 | 49x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Unjha Formulations Ltd Quarterly Performance
Latest quarterly metrics for UNJHAFOR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
13.49%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
845.45%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
5.53%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
5.75%
Compounded annual net profit growth over 5 years
Unjha Formulations Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for UNJHAFOR — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Unjha Formulations Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Unjha Formulations Ltd (UNJHAFOR) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Unjha Formulations Ltd
About UNJHAFOR (Unjha Formulations Ltd)
Unjha Formulations Ltd is a distinguished player in the Indian pharmaceutical landscape, deeply rooted in the ancient wisdom of Ayurveda. The company is committed to crafting and d...istributing a range of traditional health and wellness products, primarily focused on leveraging the therapeutic potential of natural ingredients. With a strong emphasis on quality and efficacy, Unjha Formulations aims to provide accessible and reliable Ayurvedic solutions to meet the diverse healthcare needs of the Indian population. Their commitment to preserving and promoting this time-tested system of medicine is evident in their dedication to sourcing the finest raw materials and employing rigorous manufacturing processes. Unjha Formulations strives to bridge the gap between traditional healing practices and modern pharmaceutical standards. The company's flagship offerings revolve around the widely recognized benefits of Isabgol, a natural dietary fiber. Unjha Formulations innovatively presents Isabgol in palatable and convenient formats, catering to consumer preferences. They expertly blend the inherent benefits of this natural ingredient with appealing flavors, creating user-friendly products designed to support digestive health and overall well-being. This approach allows Unjha Formulations to effectively reach a broader audience, making the advantages of Ayurveda more accessible and enjoyable. Through a dedication to innovation and consumer-centric product development, they have solidified their position as a trusted provider of natural health solutions within the competitive Indian market. Furthermore, Unjha Formulations extends its reach beyond domestic borders through its export operations. By sharing the benefits of authentic Ayurvedic products with international markets, the company contributes to the growing global recognition and acceptance of traditional Indian medicine. This expansion strategy not only strengthens the company's financial standing but also showcases the rich heritage of Indian healthcare practices on a worldwide stage. From its base in Sidhpur, India, Unjha Formulations continues to build upon its legacy of providing quality Ayurvedic products, driven by a commitment to innovation, ethical practices, and the well-being of its consumers.
Company Details
Key Leadership
UNJHAFOR Share Price: Frequently Asked Questions
What is the current share price of Unjha Formulations Ltd?
Unjha Formulations Ltd (UNJHAFOR) trades at ₹19.50 on NSE and BSE. Market cap ₹10.96 (Cr). Educational data only.
What is the P/E ratio of Unjha Formulations Ltd?
Unjha Formulations Ltd has a P/E of 10.74x vs industry average 31.77x.
What is the Bull Run score for Unjha Formulations Ltd?
Unjha Formulations Ltd has a Bull Run score of 38.8/100 based on 25+ financial parameters.
Does Unjha Formulations Ltd pay dividends?
Unjha Formulations Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Unjha Formulations Ltd?
Unjha Formulations Ltd has ROE of 13.97%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Unjha Formulations Ltd?
Unjha Formulations Ltd has debt-to-equity of 0.00.
Is Unjha Formulations Ltd a good investment?
Bull Run gives Unjha Formulations Ltd a score of 38.8/100. This is not investment advice — consult a SEBI-registered advisor.